Inflammation and Occlusive Retinal Vasculitis Post Faricimab.

ABSTRACT:

Importance

Randomized clinical trials have shown the safety and efficacy of faricimab as a novel vascular endothelial growth factor and angiopoietin-2 inhibitor in the treatment of neovascular age-related macular degeneration (nAMD) and macular edema of various etiologies. However, more rare adverse events may not be considered in clinical trials.

Objective

To describe 3 eyes that developed irreversible vision loss following initial mild intraocular inflammation (IOI) to faricimab.

Design, setting, and participants

This retrospective case series from a single academic tertiary referral center (University of Nebraska Medical Center) from October 2023 to August 2024 included 3 patients who developed occlusive retinal vasculitis (ORV) following an initial sensitization w

SUBMITTER: Bruening W 

PROVIDER: S-EPMC11926656 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature